Please use this identifier to cite or link to this item:
|Title:||An update on adrenocortical cell lines of human origin||Authors:||Sigala, Sandra
Bornstein, Stefan R.
|Keywords:||Science::Medicine||Issue Date:||2022||Source:||Sigala, S., Rossini, E., Abate, A., Tamburello, M., Bornstein, S. R. & Hantel, C. (2022). An update on adrenocortical cell lines of human origin. Endocrine, 77(3), 432-437. https://dx.doi.org/10.1007/s12020-022-03112-w||Journal:||Endocrine||Abstract:||Adrenocortical carcinoma (ACC) is a rare, heterogenous and highly malignant disease. Management of ACC is dependent on disease stage with complete surgical resection as the only potentially curative option. However, advanced, un-resectable, metastatic stages and also recurrences often require systemic treatments, which are unfortunately nowadays still unsatisfactory. The scarcity of preclinical models reflecting patient heterogeneities and furthermore drug-resistant phenotypes, has hampered the progress and development of new therapies in recent years. In this review, we provide an overview on the classical models and substantial progress which has been made over the last years in context of this aggressive disease.||URI:||https://hdl.handle.net/10356/163849||ISSN:||1355-008X||DOI:||10.1007/s12020-022-03112-w||Schools:||Lee Kong Chian School of Medicine (LKCMedicine)||Rights:||© The Author(s) 2022. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.||Fulltext Permission:||open||Fulltext Availability:||With Fulltext|
|Appears in Collections:||LKCMedicine Journal Articles|
Updated on Dec 4, 2023
Web of ScienceTM
Updated on Oct 28, 2023
Updated on Dec 8, 2023
Updated on Dec 8, 2023
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.